

EMLc
ATC codes: [J05AF05](#)

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified <span>ICD11 code: <a href="#">1C62.Z</a></span>
INN	Lamivudine
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Liquid: 50 mg per 5 mL (EMLc) Oral > Solid: 150 mg tablet
EML status history	First added in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2017 ( <a href="#">TRS 1006</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Lamivudine</a> 
DrugBank	<a href="#">Lamivudine</a> 

## Summary of evidence and Expert Committee recommendations

Noting the advice from the WHO Department of HIV/AIDS about the continued recommendation in current WHO guidelines for use of lamivudine oral liquid for the treatment of newborns, the Expert Committee recommended that it be deleted from the EML but retained on the EMLc.

